Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) posted its quarterly earnings results on Tuesday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07, Zacks reports.

Replimune Group Trading Down 2.1 %

Replimune Group stock traded down $0.26 during mid-day trading on Wednesday, hitting $11.93. 132,344 shares of the company’s stock were exchanged, compared to its average volume of 1,036,191. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $12.97. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $815.06 million, a P/E ratio of -3.91 and a beta of 1.19. The company’s 50 day simple moving average is $11.42 and its 200-day simple moving average is $9.49.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 8.80% of the company’s stock.

Analyst Ratings Changes

REPL has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Tuesday. Finally, Roth Mkm began coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $16.80.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.